MedTrace Logo

Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug

NCT01098162 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 576

Last updated 2014-09-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to systematically and prospectively collect data from patients with partial-onset seizures in routine clinical practice setting receiving adjunctive Vimpat®. The observed population will be only patients with one baseline antiepileptic drug. Seizure control and tolerability data will be evaluated.

Conditions

  • Epilepsies, Partial

Sponsors & Collaborators

  • UCB Pharma GmbH

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · +1 877 822 9493 (UCB)

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01098162 on ClinicalTrials.gov